Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), a Japanese in vitro diagnostics company, and MolecularMD Corporation (HQ: Portland, Oregon, United States; President and CEO: Dan Snyder), a molecular diagnostics company, announced today a master collaboration agreement targeting the challenges in current and future companion diagnostics (CDx)* development and commercialization needed to accelerate precision medicine.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has launched a super-resolution fluorescence microscope, the HM-1000 single-molecule fluorescence microscope, for research use. Employing super-resolution imaging technology, the HM-1000 achieves high spatial resolution1 (of less than 40nm), going beyond the limits of conventional fluorescence microscopes. As a result, the HM-1000 can be used for minute observation, such as the morphology of tiny proteins that exist within cells and the distribution of genes. Sysmex expects the HM-1000 to contribute toward effective R&D related to next-generation therapeutic drugs and diagnostic methods that will lead toward the realization of personalized medicine, as well as to developments in cellular biology.